St Jude's Epiducer now global with US clearance; gets go-ahead for BROADENing DBS study
This article was originally published in Clinica
Executive Summary
St Jude Medical has received the green light to market its Epiducer neurostimulation lead delivery system in the US. The 510(k) clearance from the FDA comes over a year after the system was CE marked; it is now currently St Jude's best-selling neurostimulation lead delivery system in Europe, the firm had told Clinica at the annual International Neuromodulation Society meeting in London earlier this year (www.clinica.co.uk, 25 May 2011).